US Compounding
US Compounding, Inc. is a privately held FDA-registered 503B drug compounding outsourcing facility founded in 2004 in Conway, United States, producing sterile compounded medications for U.S. hospitals, clinics, and licensed healthcare providers under cGMP standards.
- Company typePrivate
- Founded2004
- HeadquartersConway, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What US Compounding does
US Compounding, Inc. ("USC") is a privately held, for-profit drug compounding outsourcing facility registered with the U.S. Food and Drug Administration under Section 503B of the Federal Food, Drug, and Cosmetic Act. Founded in 2004 and headquartered in Conway, United States, USC manufactures sterile compounded preparations (such as injectables and other ready-to-administer dosages) for healthcare institutions, supplying hospitals, clinics, and other licensed providers that need regulatory-grade compounded medications that are not commercially available from traditional pharmaceutical manufacturers. As a 503B outsourcing facility, USC is required to operate under current Good Manufacturing Practice (cGMP) standards and is subject to direct FDA inspection, which distinguishes it from traditional 503A state-licensed compounding pharmacies.
The company employs 51-100 people and generates revenue through B2B supply arrangements with healthcare institutions, typically structured around per-unit pricing of compounded sterile preparations, with demand drivers including drug shortages, product discontinuation, and patient-specific clinical needs. Its customer base is institutional rather than retail, and its geographic footprint serves the U.S. market from its Conway base. Publicly disclosed information on pricing specifics, customer mix, exact product portfolio, regulatory certifications beyond 503B registration, leadership team, partnerships, and financial performance is not present in the provided data, which constrains deeper analysis of revenue mechanics, customer economics, and competitive positioning.
The 503B outsourcing facility segment is a small, regulated niche within U.S. pharmaceutical services, populated by a limited number of FDA-registered outsourcers. USC's two-decade operating history suggests an established position, but absent headcount trend, capital structure, product line, and revenue disclosures, the company's current scale, growth pace, and competitive standing relative to other 503B outsourcers cannot be quantified from the available evidence.
US Compounding firmographics
Firmographics- Name
- US Compounding
- Website
- https://uscompounding.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- US Compounding, Inc. is a privately held FDA-registered 503B drug compounding outsourcing facility founded in 2004 in Conway, United States, producing sterile compounded medications for U.S. hospitals, clinics, and licensed healthcare providers under cGMP standards.
- Ownership category
- akta.pro rank
Where US Compounding is headquartered
LocationHeadquarters
- HQ city
- Conway
- HQ country
- United States
- HQ region
- North America
Markets served
US Compounding business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
US Compounding product offering
Product offeringCore offering
US Compounding, Inc. (USC) is a privately held drug compounding outsourcing facility that prepares and supplies custom compounded pharmaceutical preparations, including sterile and non-sterile compounded medications, for licensed healthcare providers and patients. Operating as a registered outsourcing facility, USC produces quality-controlled compounded drug preparations under pharmaceutical manufacturing standards.
Differentiator
Problem solved
Functional benefit
Products and services
- Compounded pharmaceutical preparations (outsourcing facility) Custom compounded drug preparations (sterile and non-sterile), produced under outsourcing-facility quality standards and supplied to licensed U.S. healthcare providers (hospitals, clinics, physician offices) and patients requiring medications not commercially available in the required form or quantity.
Companies that use US Compounding
Customer profileIdeal customer profiles1 record
US Compounding technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
US Compounding competitors and assessment
Company assessmentDirect peers
- McGuff Compounding Pharmacy Services: 503A/503B-registered outsourcing compounder serving clinics and hospitals with sterile and non-sterile preparations; comparable in scale and customer mix to a privately-held regional outsourcing facility.
- Empower Pharmacy: One of the largest FDA-registered 503B outsourcing facilities in the U.S., producing sterile and non-sterile compounded preparations for hospitals, clinics, and patients — directly comparable in regulatory category and product mix to US Compounding.
- QuVa Pharma: A large-scale FDA-registered 503B sterile compounding outsourcing facility serving hospitals and health systems nationwide. Closest competitor profile to US Compounding in terms of cGMP-compliant outsourcing manufacturing.
- Leiters (Leiters Health): FDA-registered 503B outsourcing facility specializing in sterile admixture and ophthalmic preparations for hospital systems. Comparable outsourcing-facility business model and sterile compounding focus.
- SCA Pharmaceuticals: 503B-registered outsourcing compounder producing sterile injectable and non-sterile preparations for hospitals; serves the same provider customer base with overlapping regulatory and product scope.
- Wedgewood Pharmacy: Large specialty compounding pharmacy producing both sterile and non-sterile preparations for human and veterinary providers; similar compounding-centric operating model though stronger on the animal-health side.
Broad incumbents
- Central Admixture Pharmacy Services (CAPS): The largest hospital-focused sterile admixture outsourcing network in the U.S., owned by B. Braun. Comparable 503B outsourcing model but at substantially larger national scale, representing the upper bound of competitive intensity.
- Avella Specialty Pharmacy: Specialty pharmacy with significant compounding capability serving providers and payors; overlaps with US Compounding on compounded products but operates a broader specialty-pharmacy portfolio.
- Fagron: Global leader in pharmaceutical compounding supplies and operator of compounding pharmacies; while a competitor on the services side, its primary scale comes from supplying APIs and bases to compounders like US Compounding.
Others
- PCCA (Professional Compounding Centers of America): Supplier of APIs, bases, equipment, and training to compounding pharmacies including US Compounding-type operations; not a direct service competitor but an ecosystem participant that defines the supply landscape.
Market position
Strengths4 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
US Compounding social profiles
Digital presenceUS Compounding financial estimates
Financial estimateRevenue estimate
Valuation estimate
US Compounding leadership team
Management profileNumber of profiles
US Compounding funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
US Compounding M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about US Compounding
What does US Compounding do?
US Compounding, Inc. (USC) is a privately held drug compounding outsourcing facility that prepares and supplies custom compounded pharmaceutical preparations, including sterile and non-sterile compounded medications, for licensed healthcare providers and patients. Operating as a registered outsourcing facility, USC produces quality-controlled compounded drug preparations under pharmaceutical manufacturing standards.
When was US Compounding founded?
US Compounding was founded in 2004. It employs 51 to 100 people.
Where is US Compounding based?
US Compounding is headquartered in Conway, United States, in the North America region.
Who are US Compounding's main competitors?
Direct peers on record are McGuff Compounding Pharmacy Services, Empower Pharmacy, QuVa Pharma, Leiters (Leiters Health), SCA Pharmaceuticals and Wedgewood Pharmacy. Broad incumbents are Central Admixture Pharmacy Services (CAPS), Avella Specialty Pharmacy and Fagron. PCCA (Professional Compounding Centers of America) is listed as an others.
Does US Compounding have an API?
No public API is recorded for US Compounding.